- Human pathology

Home > D. General pathology > Blood and immunity > erythroid-predominant myelodysplastic syndrome

erythroid-predominant myelodysplastic syndrome

Wednesday 15 October 2008

- In erythroid-predominant myelodysplastic syndrome, blast calculation as a proportion of marrow nonerythroid rather than total nucleated cells can better stratify patients into prognostically relevant groups. (18839018)

Nota bene: In the FAB (French-American-British) and WHO (World Heath Organization) classifications, the blasts in erythroleukemia (M6a) are enumerated from the marrow nonerythroid rather than the total-nucleated cells. However, the method for blast calculation in erythroid-predominant myelodysplastic syndrome (erythroblasts>/=50%) is not specified either in the FAB or WHO classifications.

See also

- myelodysplastic syndromes


- Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, Hasserjian RP. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008 Sep 12. PMID: 18839018